Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 FibroGenI-MabChemoCentryxEidos TherapeuticsHutchison China MediTech
SymbolNASDAQ:FGENNASDAQ:IMABNASDAQ:CCXINASDAQ:EIDXNASDAQ:HCM
Price Information
Current Price$21.12$58.42$46.26$122.21$29.75
52 Week RangeHoldBuyBuyHoldBuy
MarketRank™
Overall Score1.81.21.61.01.4
Analysis Score4.12.53.51.03.5
Community Score2.53.32.72.32.7
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.71.70.0
Earnings & Valuation Score0.60.00.00.00.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyHoldBuy
Consensus Price Target$45.83$70.00$80.78$54.07$40.00
% Upside from Price Target117.01% upside19.82% upside74.62% upside-55.76% downside34.45% upside
Trade Information
Market Cap$1.94 billion$4.20 billion$3.23 billion$4.75 billion$4.33 billion
Beta1.59N/A1.7-0.161.12
Average Volume1,488,074361,200487,513128,113232,528
Sales & Book Value
Annual Revenue$256.58 million$4.31 million$36.13 million$26.69 million$204.89 million
Price / Sales7.58975.2189.30177.9921.14
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$6.14 per share$3.34 per share$1.14 per share$4.57 per share$2.35 per share
Price / Book3.4417.4940.5826.7412.66
Profitability
Net Income$-76,970,000.00$-208,560,000.00$-55,490,000.00$-37,830,000.00$-106,020,000.00
EPS($0.89)($28.90)($0.98)($1.03)($0.80)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-191.78%N/A-58.10%N/AN/A
Return on Equity (ROE)-48.19%N/A-17.23%-65.21%N/A
Return on Assets (ROA)-27.72%N/A-11.07%-53.04%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.05%0.14%0.07%
Current Ratio6.23%N/A10.12%11.10%3.14%
Quick Ratio6.13%N/A10.12%11.10%3.01%
Ownership Information
Institutional Ownership Percentage75.05%16.64%80.67%31.40%33.45%
Insider Ownership Percentage3.39%N/A9.30%70.10%N/A
Miscellaneous
Employees599185133701,280
Shares Outstanding92.07 million71.95 million69.74 million38.87 million145.62 million
Next Earnings Date5/6/2021 (Estimated)N/A4/29/2021 (Confirmed)N/AN/A
OptionableOptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Hutchison China MediTech secured $100M equity investment by Baring Private Equity AsiaHutchison China MediTech secured $100M equity investment by Baring Private Equity Asia
seekingalpha.com - April 9 at 7:54 PM
HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity AsiaHUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia
finance.yahoo.com - April 8 at 8:26 AM
Supernus Pharmaceuticals (NASDAQ:SUPN) versus Hutchison China MediTech (NASDAQ:HCM) Financial AnalysisSupernus Pharmaceuticals (NASDAQ:SUPN) versus Hutchison China MediTech (NASDAQ:HCM) Financial Analysis
americanbankingnews.com - April 5 at 2:14 AM
Head-To-Head Survey: Hutchison China MediTech (NASDAQ:HCM) vs. Supernus Pharmaceuticals (NASDAQ:SUPN)Head-To-Head Survey: Hutchison China MediTech (NASDAQ:HCM) vs. Supernus Pharmaceuticals (NASDAQ:SUPN)
americanbankingnews.com - April 5 at 2:14 AM
HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological MalignanciesHUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies
finance.yahoo.com - March 29 at 3:28 AM
HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 MillionHUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million
finance.yahoo.com - March 24 at 10:33 AM
Hutchison China Medi - Vesting of awards under Long Term Incentive PlanHutchison China Medi - Vesting of awards under Long Term Incentive Plan
proactiveinvestors.co.uk - March 10 at 6:35 AM
Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates ...Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates ...
apnews.com - March 4 at 7:38 AM
Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate IdentityHutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity
markets.businessinsider.com - March 4 at 7:38 AM
Hutchison China MediTech Ltd. to Host Earnings CallHutchison China MediTech Ltd. to Host Earnings Call
finance.yahoo.com - March 4 at 7:38 AM
Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate IdentityHutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity
finance.yahoo.com - March 4 at 7:38 AM
Hutchison China Medi - Notice of ResultsHutchison China Medi - Notice of Results
proactiveinvestors.co.uk - February 4 at 8:30 AM
Hutchison China Meditech (HCM) ORD USD0.10Hutchison China Meditech (HCM) ORD USD0.10
hl.co.uk - January 23 at 6:48 PM
Hutchison China Medi - Savolitinib Data to be Presented at Virtual WCLCHutchison China Medi - Savolitinib Data to be Presented at Virtual WCLC
proactiveinvestors.co.uk - January 15 at 10:15 PM
Hutchison China Medi - Chi-Med & Inmagene Announce Strategic PartnershipHutchison China Medi - Chi-Med & Inmagene Announce Strategic Partnership
proactiveinvestors.co.uk - January 12 at 1:41 AM
Chi-Med, Inmagene To Develop & Commercialize Portfolio Of Drug Candidates For Immunological Diseases Chi-Med, Inmagene To Develop & Commercialize Portfolio Of Drug Candidates For Immunological Diseases
markets.businessinsider.com - January 10 at 9:54 PM
Hutchison China Medi - Total Voting RightsHutchison China Medi - Total Voting Rights
proactiveinvestors.co.uk - January 1 at 11:16 PM
Hutchison China Medi - NMPA approval of Surufatinib in China for ep-NETHutchison China Medi - NMPA approval of Surufatinib in China for ep-NET
proactiveinvestors.co.uk - December 30 at 1:35 PM
Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine TumorsChi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors
finance.yahoo.com - December 30 at 8:35 AM
Hutchison China Medi - US NDA Rolling Submission of Surufatinib InitiatedHutchison China Medi - US NDA Rolling Submission of Surufatinib Initiated
proactiveinvestors.co.uk - December 29 at 9:07 AM
Hutchison China Files US FDA Drug Application For Cancer TreatmentHutchison China Files US FDA Drug Application For Cancer Treatment
lse.co.uk - December 29 at 9:07 AM
Hutchison China Medi - Chi-Med to Present at JPMHutchison China Medi - Chi-Med to Present at JPM
proactiveinvestors.co.uk - December 22 at 2:13 PM
Should I Avoid Hutchison China MediTech Limited (HCM)?Should I Avoid Hutchison China MediTech Limited (HCM)?
finance.yahoo.com - December 1 at 2:27 AM
China NMPA accepts for review Chi-Med’s NDA for surufatinib to treat advanced pancreatic neuroendocrine tumorsChina NMPA accepts for review Chi-Med’s NDA for surufatinib to treat advanced pancreatic neuroendocrine tumors
pharmabiz.com - September 19 at 10:03 AM
Chinas NMPA accepts Hutchison China MediTechs surufatinib applicationChina's NMPA accepts Hutchison China MediTech's surufatinib application
seekingalpha.com - September 18 at 2:00 PM
DateCompanyBrokerageAction
4/13/2021FibroGenJPMorgan Chase & Co.Upgrade
4/13/2021FibroGenHC WainwrightReiterated Rating
4/13/2021FibroGenSVB LeerinkLower Price Target
4/13/2021FibroGenMizuhoReiterated Rating
4/7/2021FibroGenRaymond JamesReiterated Rating
3/31/2021FibroGenBank of AmericaUpgrade
3/8/2021FibroGenJefferies Financial GroupReiterated Rating
5/1/2020FibroGenCowenInitiated Coverage
3/19/2020FibroGenCitigroupLower Price Target
3/22/2021I-MabNeedham & Company LLCInitiated Coverage
3/3/2021I-MabPiper SandlerInitiated Coverage
9/8/2020I-MabCantor FitzgeraldBoost Price Target
2/13/2020I-MabCICC ResearchInitiated Coverage
2/12/2020I-MabChina Renaissance SecuritiesInitiated Coverage
3/8/2021ChemoCentryxStifel NicolausInitiated Coverage
10/29/2020ChemoCentryxWells Fargo & CompanyLower Price Target
6/16/2020ChemoCentryxBTIG ResearchInitiated Coverage
6/3/2020ChemoCentryxCanaccord GenuityReiterated Rating
12/30/2020Eidos TherapeuticsSmith Barney CitigroupReiterated Rating
10/6/2020Eidos TherapeuticsBMO Capital MarketsDowngrade
9/22/2020Eidos TherapeuticsGuggenheimDowngrade
5/11/2020Eidos TherapeuticsBarclaysLower Price Target
11/19/2019Eidos TherapeuticsPiper Jaffray CompaniesBoost Price Target
11/1/2019Eidos TherapeuticsRoth CapitalBoost Price Target
10/2/2020Hutchison China MediTechDeutsche Bank AktiengesellschaftInitiated Coverage
2/20/2020Hutchison China MediTechThe Goldman Sachs GroupInitiated Coverage
11/19/2019Hutchison China MediTechCLSAInitiated Coverage
7/5/2019Hutchison China MediTechMacquarieInitiated Coverage
3/27/2019Hutchison China MediTechHSBCInitiated Coverage
(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.